Lineage Cell Therapeutics, Inc.
$1.03
$0.00 (+0.00%)
$1.00Day Range$1.05
Key Statistics
Market Cap
$260.49M
Shares Outstanding
252.9M
Primary Exchange
XASE
Currency
USD
Type
CS
IPO Date
Mar 5, 1992
Round Lot
100
Locale
US
Trading Data
Day Open
$1.02
Day High
$1.05
Day Low
$1.00
Volume
3.21M
VWAP
$1.03
Prev Close
$1.03
Transactions
--
Acc. Volume
--
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283677 employees2173 SALK AVENUE, CARLSBAD, CA, 92008(510) 521-3390IPO Mar 5, 1992US / STOCKSActiveWebsite
Identifiers
- CIK
- 0000876343
- Composite FIGI
- BBG000G8RJY6
- Share Class FIGI
- BBG001SCW8V3
- Ticker Root
- LCTX
- SIC Code
- 2836
About Lineage Cell Therapeutics, Inc. (LCTX) Stock
Lineage Cell Therapeutics, Inc. (LCTX) closed the 2026-09-18 session at $1.03, up 0.00% versus the previous close (+0.00). The stock opened at $1.02 and traded between $1.00 and $1.05 during that session. Session trading volume was 3.2M shares. The volume-weighted average price (VWAP) is $1.03.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
Lineage Cell Therapeutics, Inc. has a market capitalization of $260.5 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. LCTX is listed on the XASE exchange. The company employs approximately 77 people. Lineage Cell Therapeutics, Inc. is headquartered in CARLSBAD, CA. The recorded listing date is 1992-03-05.
On this page you can find market LCTX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.